• Explore /
  • Poster
  • / Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.

Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.

Abstract Poster

Authors

null

Matthieu Delaye

Medical Oncology Department, Curie Institute, Saint-Cloud, France

Matthieu Delaye , Eric Assenat , Laetitia Dahan , Jean-Frédéric Blanc , David Tougeron , Jean-Philippe Metges , Astrid Lievre , Anthony Turpin , Nadim Fares , Christelle De La Fouchardiere , Hélène Castanie , Jérôme Desrame , Anna Pellat , Thierry Lecomte , Anne Laure Bignon , Vincent Hautefeuille , Marie-Line Garcia-Larnicol , Antoine Falcoz , Meher Ben Abdelghani , Cindy Neuzillet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03704480

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4108)

DOI

10.1200/JCO.2022.40.16_suppl.4108

Abstract #

4108

Poster Bd #

95

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Ignacio Matos Garcia

First Author: Sadahisa Ogasawara

First Author: Olumide B. Gbolahan